
SciSparc Ltd. (NASDAQ:SPRC) collaboration with Clearmind Medicine Inc. (OTCPK:CMNDF) (CSE:CMND) (FSE:CWY0) resulted in the filing of a provisional patent application related to treating cocaine addiction.
The patent application refers to the proprietary combination of SciSparc's CannAmide with Clearmind's MEAI, for treating cocaine addiction.